logo
Questions? +1 (202) 335-3939 Login
Set Up FREE Account Submit Release
Trusted News Since 1995
A service for pharmaceutical industry professionals · Saturday, April 5, 2025 · 800,397,952 Articles · 3+ Million Readers
Home  •••  Newswires by Industry  •  Countries  •  U.S. States  •  World Media Directory
Pharmaceutical Industry News  •••  Topics  •  Countries  •  U.S. States

Ustekinumab News Monitoring

  • Published on Apr 4, 2025

    Commercialization of Ustekinumab and Golimumab Biosimilars

    This Monday, Bio-Thera Solutions and Dr. Reddy’s Laboratories SA announced that they had entered into commercialization and licensing agreements for proposed ustekinumab and golimumab biosimilars in Southeast Asia.  Bio-Thera will develop, manufacture, and …

    Source: JD Supra - California - Neutral
  • Published on Apr 3, 2025

    European Commission approves ustekinumab for paediatric Crohn’s disease

    Approval extends ustekinumab’s use to younger patients The European Commission (EC) has approved ustekinumab for the treatment of moderately to severely active Crohn’s disease in paediatric patients weighing at least 40 kg. The decision follows evidence of …

    Source: PharmaTimes - Neutral
  • Published on Apr 3, 2025

    Successful Treatment of Ustekinumab-Associated Lichenoid Drug Eruption with Upadacitinib: A Case Report

    Introduction Ustekinumab is a fully human monoclonal antibody against the common p40 subunit of IL-12 and IL-23, with exact efficacy for moderate-to-severe psoriasis by inhibiting Th1 and Th17/Th22 responses.1 The most commonly associated adverse …

    Source: Dove Medical Press - Neutral
  • Published on Mar 31, 2025

    Idarucizumab, levetiracetam, ustekinumab: how do drugs get their names and why are they so hard to pronounce?

    If you’ve ever tried discussing medicines with friends or family and found yourself stumbling over the pronunciation — or even resorting to snapping a photo of the medicine’s packaging to show your pharmacist, instead of remembering the name — you’ve …

    Source: The Conversation - Neutral
  • Published on Mar 31, 2025

    FDA News Month in Review: March 2025

    Welcome back to our recap of this month's news and updates from the US Food and Drug Administration (FDA)! In our March 2025 recap, we spotlight 13 FDA decisions, including 12 approvals or clearances and 1 Refusal to File letter. Be sure to subscribe …

    Source: HCPLive - Neutral
  • Published on Mar 31, 2025

    TREMFYA receives positive CHMP opinion for treatment of patients with Crohn's

    Johnson & Johnson has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended expanding the Marketing Authorisation for TREMFYA (guselkumab) to include the treatment of adult …

    Source: European Pharmaceutical Manufacturer - Neutral
  • Published on Mar 31, 2025

    PASI and QoL: A New Approach to Treatment Goals

    Psoriasis is a chronic inflammatory skin disorder that significantly impacts patients' quality of life (QoL). Characterized by erythematous plaques with scaling, psoriasis not only causes physical discomfort but also has profound psychological and …

    Source: Dermatology Times - Neutral
  • Published on Apr 1, 2025

    Oral Therapies Take Center Stage For PsO And PsA Treatment

    By Jack Gordon and Adam Pow, Lifescience Dynamics The recent American Academy of Dermatology (AAD) 2025 Annual Meeting in Florida in early March saw major updates for two key oral therapies in autoimmune diseases: J&J’s icotrokinra and BMS’ Sotyktu ( …

    Source: Outsourced Pharma - Label Pending
  • Published on Apr 3, 2025

    Johnson & Johnson announces European Commission approval

    Johnson & Johnson has announced that the European Commission (EC) has approved a Marketing Authorisation for STELARA (ustekinumab) to include the treatment of moderately to severely active Crohn’s disease in paediatric patients weighing at least 40 kg, …

    Source: European Pharmaceutical Manufacturer - Neutral
  • Published on Apr 3, 2025

    Gastroenterology Month in Review: March 2025

    March was a major month for gastroenterology, bringing a key US Food and Drug Administration (FDA) approval, clinical trial progress, and new guidance on colorectal cancer screening. A 6-part HCPLive RX Review explored the latest US Multi-Society Task …

    Source: Consultant Live - Label Pending
  • Published on Apr 2, 2025

    Rheumatology Month in Review: March 2025

    March brought significant advancements in rheumatology, spanning gout, psoriatic arthritis (PsA), and fibromyalgia. In gout, SAP-001 from Shanton Pharma showed best-in-class efficacy in a phase 2b trial, with most patients achieving target uric acid levels …

    Source: Consultant Live - Label Pending
  • Published on Apr 1, 2025

    Biosimilars Gastroenterology Roundup: March 2025

    In March 2025, the biosimilar industry marked a decade of transformative growth, with a surge in approvals and widespread adoption, though challenges around interchangeability, pharmacy benefit manager (PBM) influence, and regulatory reforms continue to …

    Source: The Center for Biosimilars - Label Pending
  • Published on Mar 31, 2025

    Biosimilars Help Alvotech Revenues Soar Over 400% Year Over Year

    Thanks to its successful biosimilar portfolio, Alvotech revenues jumped 427% in 2024 compared with 2023, showing immense growth year over year and proving that biosimilars are a profitable avenue for biopharmaceutical companies.1 Alvotech is an Iceland- …

    Source: The Center for Biosimilars - Label Pending
  • Published on Apr 3, 2025

    PBM Private Labeling Boosts Biosimilars, Raises Concerns

    Nearly 2 years after entering the market, adalimumab biosimilars are finally seeing traction. CVS Health’s Caremark, Cigna’s Express Scripts, and UnitedHealth Group’s OptumRx, which are pharmacy benefit managers (PBMs) that collectively control about 80% …

    Source: Medscape - Neutral
  • Published on Apr 3, 2025

    March Stelara® Biosimilar Launches: Fresenius Kabi’s Otulfi® and Celltrion’s Steqeyma™

    On March 3, 2025, Fresenius Kabi and Formycon announced the launch of Otulfi™ (ustekinumab-aauz), a provisionally interchangeable biosimilar of Janssen / Johnson & Johnson’s Stelara® (ustekinumab), subject to the interchangeable exclusivity of …

    Source: JD Supra - California - Neutral
  • Published on Apr 3, 2025

    How Pharmacy Deserts, Biosimilars, and Market Trends Are Shaping Managed Care

    Rising biosimilar adoption, shifting pharmaceutical market dynamics, and mounting supply chain vulnerabilities are reshaping managed care, presenting both challenges and opportunities for industry stakeholders. At AMCP 2025, the annual meeting of the …

    Source: The American Journal of Managed Care - Neutral
  • Published on Apr 1, 2025

    ANTHEM-UC: Icotrokinra (JNJ-2113) Shows Promise for Ulcerative Colitis

    Key Takeaways Icotrokinra achieved primary and secondary endpoints in ulcerative colitis, showing significant clinical response and remission rates compared to placebo. The investigational oral peptide selectively blocks the IL-23 receptor, offering a …

    Source: The American Journal of Managed Care - Neutral
  • Published on Mar 31, 2025

    Johnson & Johnson’s Tremfya recommended by CHMP to treat Crohn’s disease

    Johnson & Johnson (J&J) has announced that its Tremfya (guselkumab) has been recommended by the European Medicines Agency’s human medicines committee to treat Crohn’s disease (CD). The Committee for Medicinal Products for Human Use (CHMP) has …

    Source: PMLiVE - Neutral
  • «
  • 1
  • »

02 days 23:27:39

Featured Releases

Got News to Share? · Submit · See All
Got news to share? Submit it now.
Load more pharmaceuticals news or search news using your own keywords. There are 800,397,952 articles in our news database.

Online News Monitoring Made Simple

Established in 1995, EIN Newsdesk helps millions of users track breaking news across thousands of trusted websites. Users may set up custom email newsletters and RSS feeds or search among thousands of preset news sections. As a member, you may also submit your own news using the EIN Presswire distribution service. Membership is free and we do not sell or lease any information about you. Press release distribution, dedicated APIs, and custom services generate the revenue that allow us to offer you free basic access.

News by Country & by Industry

Worldwide News Coverage

Track news across more than 5,000 sources by country or industry or search our real-time news index.

Pharmaceutical Industry News by Country >
Pharmaceutical Industry News by U.S. State >
Pharmaceutical Industry News Topics >
Online News Publications >
World News Report >

News Alerts & News Feeds

Custom News Monitoring

News page results can be outputted as RSS or received daily by email. You may also use our NewsPlugin for WordPress.

Create Email Newsletter >
Create RSS Feed >
NewsPlugin for WordPress >

Submit News

PR Distribution Service

Our EIN Presswire's distribution footprint reaches millions. You can upload news which is re-published through EIN Newsdesk, fed into Twitter and Facebook, and onto partner sites, Google News, Bing News, etc.

EIN Presswire >
Events >

World Media Directory

News Media Guide

This is a listing of the world’s TV stations, radio stations, newspapers, and blogs. Last update: 03/19/2025

World Media Directory >

Healthcare & Pharmaceuticals Industry Press Releases

Got News to Share? · Submit · See All
Got news to share? Submit it now.

Healthcare & Pharmaceuticals Events

See All

No event was found.

Become a Member - Join Today!
Join thousands of professionals. Stay current. Stay competitive.
  • Track news from thousands of sources
  • Submit news sources for inclusion in our news tracking algorithm
  • Build your own customized email newsletters
  • Use of our RSS Feeds
  • Includes a complimentary EIN Presswire account plus 1-free release
  • Uncluttered & advertising free news pages

Pharmaceutical Industry Today by EIN Newsdesk & EIN Presswire (a press release distribution service)

Follow us on Facebook and connect with us on LinkedIn

Newsmatics Inc., 1025 Connecticut Avenue NW, Suite 1000, Washington, DC 20036 · Contact · About

© 1995-2025 Newsmatics Inc., a publisher of EIN News · All Rights Reserved · Privacy Policy · User Agreement